| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
2 companies
Proquest Investments IV, L.P. last filed a Form 4 in November 2017, as 10% Owner at URGN. The filings on record cover 2 companies. From August 2016 to November 2017, the filings on record show 0 open-market purchases and 16 sales.
At the last filing, the largest reported position was 1,242,031 shares of URGN. The URGN filings lean toward selling, a net 209,298 shares.
Shares as reported in the last Form 4 for each company; the most recent is from November 2017. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 30, 2016 | EGRX Eagle Pharmaceuticals, Inc. | 10% Owner | Sell | 22,100 | $70.06 | $1,548,326.00 | -0.5% | |
| Sep 29, 2016 | EGRX Eagle Pharmaceuticals, Inc. | 10% Owner | Sell | 77,900 | $70.04 | $5,456,116.00 | -1.7% | |
| Sep 21, 2016 | EGRX Eagle Pharmaceuticals, Inc. | 10% Owner | Sell | 99,795 | $66.17 | $6,603,416.03 | -77.1% | |
| Sep 8, 2016 | EGRX Eagle Pharmaceuticals, Inc. | 10% Owner | Sell | 70,925 | $62.50 | $4,432,862.85 | -70.1% | |
| Aug 24, 2016 | EGRX Eagle Pharmaceuticals, Inc. | 10% Owner | Sell | 28,870 | $63.00 | $1,818,671.06 | -48.5% | |
| Aug 17, 2016 | EGRX Eagle Pharmaceuticals, Inc. | 10% Owner | Sell | 99,795 | $61.36 | $6,123,170.01 | -76.4% |